

**UNITED STATES SECURITIES AND EXCHANGE
COMMISSION**

Washington, D.C. 20549

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF
SECURITIES**

OMB APPROVAL

OMB Number: 3235-0104

Estimated average burden

hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Leoni Mollie</u> (Last) (First) (Middle) <u>C/O KURA ONCOLOGY, INC.</u> <u>12730 HIGH BLUFF DRIVE, SUITE</u> <u>400</u> (Street) <u>SAN</u> <u>CA</u> <u>92130</u> <u>DIEGO</u> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>01/02/2025</u>	3. Issuer Name and Ticker or Trading Symbol <u>Kura Oncology, Inc. [KURA]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>Chief Medical Officer</u>	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
<u>Common Stock</u>	<u>46,966⁽¹⁾</u>	<u>D</u>	

**Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
<u>Option to purchase common stock</u>	<u>(2)</u>	<u>02/09/2030</u>	<u>Common Stock</u>	<u>52,500</u>	<u>12.22</u>	<u>D</u>	
<u>Option to purchase common stock</u>	<u>(3)</u>	<u>01/25/2031</u>	<u>Common Stock</u>	<u>22,260</u>	<u>32.8</u>	<u>D</u>	
<u>Option to purchase common stock</u>	<u>(4)</u>	<u>01/25/2032</u>	<u>Common Stock</u>	<u>52,500</u>	<u>14.15</u>	<u>D</u>	
<u>Option to purchase common stock</u>	<u>(5)</u>	<u>02/15/2033</u>	<u>Common Stock</u>	<u>63,750</u>	<u>11.99</u>	<u>D</u>	
<u>Option to purchase common stock</u>	<u>(6)</u>	<u>07/02/2033</u>	<u>Common Stock</u>	<u>40,000</u>	<u>10.6</u>	<u>D</u>	
<u>Option to purchase common stock</u>	<u>(7)</u>	<u>01/01/2034</u>	<u>Common Stock</u>	<u>50,000</u>	<u>15.36</u>	<u>D</u>	

Explanation of Responses:

1. Includes 4,716 shares of common stock and 42,250 shares of common stock that may be issued pursuant to the following restricted stock unit awards (RSUs): (i) 1,781 shares pursuant to a RSU granted on 1/26/21 that will vest on 1/26/25, (ii) 7,500 shares pursuant to a RSU granted on 1/26/22 that will vest in equal installments on 1/26/25 and 1/26/26, (iii) 7,969 shares pursuant to a RSU granted on 2/16/23 that will vest in equal installments on 1/26/25, 1/26/26 and 1/26/27, and (iv) 25,000 shares pursuant to a RSU granted on 1/2/24 that will vest in equal installments on 1/26/25, 1/26/26, 1/26/27 and 1/26/28.

2. Fully Vested

3. This option vests in 48 equal monthly installments commencing on the grant date of 1/26/21.

4. This option vests in 48 equal monthly installments commencing on the grant date of 1/26/22.

5. This option vests in 48 equal monthly installments commencing on the grant date of 2/16/23.

6. This option vests in 48 equal monthly installments commencing on the grant date of 7/3/23.

7. This option vests in 48 equal monthly installments commencing on the grant date of 1/2/24.

Teresa Bair, Attorney-in-
fact for Mollie Leoni 01/07/2025

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

LIMITED POWER OF ATTORNEY FOR SECTION 16 REPORTING OBLIGATIONS

Know all by these presents, that the undersigned's hereby makes, constitutes and appoints Teresa Bair and Tom Doyle of Kura Oncology, Inc. and Charles Bair of Cooley LLP as the undersigned's true and lawful attorney- in-fact, with full power and authority as hereinafter described on behalf of and in the name, place and stead of the undersigned to:

- (1) prepare, execute, acknowledge, deliver and file Forms 3, 4, and 5 (including any amendments thereto) with respect to the securities of Kura Oncology, Inc., a Delaware corporation (the "**Company**"), with the United States Securities and Exchange Commission, any national securities exchanges and the Company, as considered necessary or advisable under Section 16(a) of the Securities Exchange Act of 1934 and the rules and regulations promulgated thereunder, as amended from time to time (the "**Exchange Act**");
- (2) seek or obtain, as the undersigned's representative and on the undersigned's behalf, information on transactions in the Company's securities from any third party, including brokers, employee benefit plan administrators and trustees, and the undersigned hereby authorizes any such person to release any such information to the undersigned and approves and ratifies any such release of information; and
- (3) perform any and all other acts which in the discretion of such attorney-in-fact are necessary or desirable for and on behalf of the undersigned in connection with the foregoing.

The undersigned acknowledges that:

- (1) this Power of Attorney authorizes, but does not require, such attorney-in-fact to act in their discretion on information provided to such attorney-in-fact without independent verification of such information;
- (2) any documents prepared and/or executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney will be in such form and will contain such information and disclosure as such attorney-in- fact, in his or her discretion, deems necessary or desirable;
- (3) neither the Company nor such attorney-in-fact assumes (i) any liability for the undersigned's responsibility to comply with the requirement of the Exchange Act, (ii) any liability of the undersigned for any failure to comply with such requirements, or (iii) any obligation or liability of the undersigned for profit disgorgement under Section 16(b) of the Exchange Act; and
- (4) this Power of Attorney does not relieve the undersigned from responsibility for compliance with the undersigned's obligations under the Exchange Act, including without limitation the reporting requirements under Section 16 of the Exchange Act.

The undersigned hereby gives and grants the foregoing attorney-in-fact full power and authority to do and perform all and every act and thing whatsoever requisite, necessary or appropriate to be done in and about the foregoing matters as fully to all intents and purposes as the undersigned might or could do if present, hereby ratifying all that such attorney-in-fact of, for and on behalf of the undersigned, shall lawfully do or cause to be done by virtue of this Limited Power of Attorney.

This Power of Attorney shall remain in full force and effect until revoked by the undersigned in a signed writing delivered to such attorney-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 7th day of January, 2025.

/s/ Mollie Leoni
Mollie Leoni